Does the media refer more to GMAB or EWTX?

In the previous week, Genmab A/S had 5 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 8 mentions for Genmab A/S and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.54 beat Genmab A/S's score of -0.04 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ASND or EWTX?

In the previous week, Ascendis Pharma A/S had 11 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.54 beat Ascendis Pharma A/S's score of 0.73 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to BBIO or EWTX?

In the previous week, BridgeBio Pharma had 10 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.54 beat BridgeBio Pharma's score of 0.26 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor AXSM or EWTX?

In the previous week, Axsome Therapeutics had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 5 mentions for Axsome Therapeutics and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.54 beat Axsome Therapeutics' score of 0.50 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to EWTX or RDY?

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 2 mentions for Dr. Reddy's Laboratories. Edgewise Therapeutics' average media sentiment score of 1.54 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Edgewise Therapeutics (EWTX) Competitors

$40.63 -0.29 (-0.71%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$40.66 +0.02 (+0.06%)

As of 06/30/2026 06:49 PM Eastern

Compare

EWTX vs. GMAB, ASND, BBIO, AXSM, and RDY

Should you buy Edgewise Therapeutics stock or one of its competitors? MarketBeat compares Edgewise Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edgewise Therapeutics include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Edgewise Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Genmab A/S has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.60	$963M	$1.32	20.81
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Genmab A/S currently has a consensus price target of $37.93, suggesting a potential upside of 38.07%. Edgewise Therapeutics has a consensus price target of $47.30, suggesting a potential upside of 16.42%. Given Genmab A/S's higher probable upside, research analysts plainly believe Genmab A/S is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Genmab A/S had 5 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 8 mentions for Genmab A/S and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.54 beat Genmab A/S's score of -0.04 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Genmab A/S has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Genmab A/S has a net margin of 21.05% compared to Edgewise Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Genmab A/S beats Edgewise Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

Ascendis Pharma A/S has a net margin of 57.87% compared to Edgewise Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Ascendis Pharma A/S currently has a consensus price target of $295.39, indicating a potential upside of 10.75%. Edgewise Therapeutics has a consensus price target of $47.30, indicating a potential upside of 16.42%. Given Edgewise Therapeutics' higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Ascendis Pharma A/S had 11 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.54 beat Ascendis Pharma A/S's score of 0.73 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Edgewise Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.43	-$258M	$8.67	30.76
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Edgewise Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Edgewise Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Edgewise Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

BridgeBio Pharma presently has a consensus target price of $92.90, suggesting a potential upside of 24.73%. Edgewise Therapeutics has a consensus target price of $47.30, suggesting a potential upside of 16.42%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 10 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.54 beat BridgeBio Pharma's score of 0.26 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

99.9% of BridgeBio Pharma shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Edgewise Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	29.05	-$724.93M	-$3.74	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Summary

BridgeBio Pharma beats Edgewise Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

In the previous week, Axsome Therapeutics had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 5 mentions for Axsome Therapeutics and 3 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.54 beat Axsome Therapeutics' score of 0.50 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Edgewise Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.73	-$183.17M	-$3.73	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Axsome Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Axsome Therapeutics presently has a consensus target price of $258.95, indicating a potential upside of 5.79%. Edgewise Therapeutics has a consensus target price of $47.30, indicating a potential upside of 16.42%. Given Edgewise Therapeutics' higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Edgewise Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Edgewise Therapeutics' return on equity of -32.55% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Edgewise Therapeutics beats Axsome Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Dr. Reddy's Laboratories?

Edgewise Therapeutics (NASDAQ:EWTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Dr. Reddy's Laboratories has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Dr. Reddy's Laboratories	$3.58B	3.38	$456M	$0.58	25.01

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 3 mentions for Edgewise Therapeutics and 2 mentions for Dr. Reddy's Laboratories. Edgewise Therapeutics' average media sentiment score of 1.54 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Edgewise Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Edgewise Therapeutics currently has a consensus price target of $47.30, suggesting a potential upside of 16.42%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Edgewise Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Edgewise Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Summary

Dr. Reddy's Laboratories beats Edgewise Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Edgewise Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EWTX vs. The Competition

Export

Metric	Edgewise Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.40B	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-24.48	20.90	27.25	24.87
Price / Sales	N/A	341.80	540.68	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	8.24	8.75	11.01	6.54
Net Income	-$167.79M	$23.81M	$3.57B	$336.70M
7 Day Performance	-3.95%	3.60%	2.31%	2.88%
1 Month Performance	0.92%	3.72%	1.39%	0.64%
1 Year Performance	216.93%	68.80%	36.71%	31.34%

Edgewise Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EWTX Edgewise Therapeutics	3.4566 of 5 stars	$40.63 -0.7%	$47.30 +16.4%	+209.9%	$4.40B	N/A	N/A	60
GMAB Genmab A/S	4.6759 of 5 stars	$25.94 +1.3%	$37.93 +46.2%	+33.0%	$16.17B	$3.72B	19.65	3,029	News Coverage
ASND Ascendis Pharma A/S	4.262 of 5 stars	$238.59 +4.6%	$295.39 +23.8%	+54.5%	$14.88B	$865.78M	27.52	1,189
BBIO BridgeBio Pharma	3.1665 of 5 stars	$68.63 -0.4%	$91.05 +32.7%	+72.5%	$13.44B	$579.96M	N/A	400
AXSM Axsome Therapeutics	1.9327 of 5 stars	$241.97 -2.4%	$258.95 +7.0%	+134.5%	$12.45B	$708.24M	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EWTX) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. GMAB, ASND, BBIO, AXSM, and RDY

How does Edgewise Therapeutics compare to Genmab A/S?

Summary

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Summary

How does Edgewise Therapeutics compare to Axsome Therapeutics?

Summary

How does Edgewise Therapeutics compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. GMAB, ASND, BBIO, AXSM, and RDY

How does Edgewise Therapeutics compare to Genmab A/S?

Which has stronger earnings & valuation, GMAB or EWTX?

Do analysts recommend GMAB or EWTX?

Does the media refer more to GMAB or EWTX?

Which has more risk & volatility, GMAB or EWTX?

Is GMAB or EWTX more profitable?

Do insiders and institutionals believe in GMAB or EWTX?

Summary

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Is ASND or EWTX more profitable?

Do analysts prefer ASND or EWTX?

Does the media favor ASND or EWTX?

Which has better valuation & earnings, ASND or EWTX?

Which has more volatility and risk, ASND or EWTX?

Summary

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Is BBIO or EWTX more profitable?

Do analysts rate BBIO or EWTX?

Which has more risk and volatility, BBIO or EWTX?

Does the media refer more to BBIO or EWTX?

Do institutionals & insiders believe in BBIO or EWTX?

Which has preferable valuation & earnings, BBIO or EWTX?

Summary

How does Edgewise Therapeutics compare to Axsome Therapeutics?

Does the media favor AXSM or EWTX?

Which has stronger earnings and valuation, AXSM or EWTX?

Which has more risk and volatility, AXSM or EWTX?

Do analysts recommend AXSM or EWTX?

Is AXSM or EWTX more profitable?

Do institutionals and insiders have more ownership in AXSM or EWTX?

Summary

How does Edgewise Therapeutics compare to Dr. Reddy's Laboratories?

Which has higher earnings & valuation, EWTX or RDY?

Does the media refer more to EWTX or RDY?

Do insiders & institutionals believe in EWTX or RDY?

Which has more risk and volatility, EWTX or RDY?

Do analysts rate EWTX or RDY?

Is EWTX or RDY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools